An Ebola outbreak in the Democratic Republic of Congo has become the deadliest in the country's history and the fastest-growing on record. It is being caused by Bundibugyo virus, a rare Ebola species.
12:41 AMBBC26 stories from 10 sources
Public-health threats rise as healthcare business faces sharper scrutiny
Day’s Recap
Supporting Articles
MMR vaccination coverage among U.S. kindergarteners has continued to decline since the COVID-19 pandemic, as measles cases rise. The falling coverage is eroding protection against a highly contagious disease.
3:39 PMCNBC
UnitedHealth is facing an IRS investigation related to its tax payments. At the same time, private equity activity in physician-group deals is slowing.
10:40 AMStat News
The IRS is examining whether UnitedHealth used arrangements that improperly reduced its tax liability. The dispute could leave the insurer facing a substantial increase in taxes.
4:30 AMStat News
EyePoint said its experimental treatment for wet age-related macular degeneration did not maintain patients' vision when injections were given less frequently than with a standard treatment. The company nevertheless said the program may still have potential.
2:45 PMStat News
EyePoint's experimental drug Duravyu failed a late-stage trial for a serious age-related eye disease, sending the company's shares down about 70%. The company plans another trial and a potential FDA submission in 2027 as it seeks to challenge Regeneron's Eylea.
11:35 AMEconomic Times
AstraZeneca is stopping a late-stage trial of volrustomig after the experimental drug appeared unlikely to outperform existing lung cancer treatments. Separate trials produced positive results, including a Tagrisso and Orpathys combination for non-small cell lung cancer.
9:57 AMBloomberg Markets
AstraZeneca is discontinuing a late-stage trial testing a drug in patients with metastatic non-small cell lung cancer. The decision adds to a recent run of setbacks for the company’s oncology pipeline.
9:22 AMStat News
Private equity deals involving practice-management firms are declining sharply, as new state laws appear to be limiting investor takeovers of physician groups.
12:01 AMStat News
A household is weighing whether a $42,000 bonus could raise its income enough to reduce or eliminate its Affordable Care Act subsidy. The financial pressure has led to advice to return the bonus and borrow against home equity.
12:00 PMMarketWatch
The article examines a family's concern that an unemployed son pays $500 a month for Affordable Care Act coverage while some people with substantial assets but low taxable income qualify for subsidies. The dispute centers on how Marketplace assistance is calculated.
3:00 PMMarketWatch12:41 AMBBC
Ebola outbreak in DR Congo becomes deadliest in its history
Summary
An Ebola outbreak in the Democratic Republic of Congo has become the deadliest in the country's history and the fastest-growing on record. It is being caused by Bundibugyo virus, a rare Ebola species.
The outbreak's speed and unprecedented death toll indicate that existing containment measures are failing to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A rapidly expanding outbreak involving a rare Ebola species raises the risk that standard response tools and local health capacity will prove insufficient.
3:39 PMCNBC
U.S. kindergarten vaccine coverage falls, CDC says
Summary
MMR vaccination coverage among U.S. kindergarteners has continued to decline since the COVID-19 pandemic, as measles cases rise. The falling coverage is eroding protection against a highly contagious disease.
The decisive shift is that routine childhood immunization has not recovered to pre-pandemic levels. Lower
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Declining kindergarten vaccination rates are turning preventable measles outbreaks into a growing national risk.
10:40 AMStat News
STAT+: The IRS is probing UnitedHealth, and a private equity slowdown
Summary
UnitedHealth is facing an IRS investigation related to its tax payments. At the same time, private equity activity in physician-group deals is slowing.
The IRS inquiry adds regulatory and financial uncertainty to UnitedHealth's already complex business, while the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Tax scrutiny and weaker private equity demand point to a more constrained environment for healthcare consolidation and financial engineering.
4:30 AMStat News
STAT+: UnitedHealth faces IRS probe over potential tax avoidance
Summary
The IRS is examining whether UnitedHealth used arrangements that improperly reduced its tax liability. The dispute could leave the insurer facing a substantial increase in taxes.
The investigation creates a direct financial risk for UnitedHealth beyond its ongoing operating pressures. It
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A major tax assessment would affect UnitedHealth's earnings and could raise compliance costs across the health insurance industry.
2:45 PMStat News
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
Summary
EyePoint said its experimental treatment for wet age-related macular degeneration did not maintain patients' vision when injections were given less frequently than with a standard treatment. The company nevertheless said the program may still have potential.
The failed comparison weakens the treatment's case as a longer-interval alternative to established therapy. EyePoint
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The result undercuts a key value proposition for a treatment aimed at reducing the burden of repeated eye injections.
11:35 AMEconomic Times
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%
Summary
EyePoint's experimental drug Duravyu failed a late-stage trial for a serious age-related eye disease, sending the company's shares down about 70%. The company plans another trial and a potential FDA submission in 2027 as it seeks to challenge Regeneron's Eylea.
The failed trial sharply weakens EyePoint's near-term path to market and leaves investors dependent on
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The result delays a potential competitor in a major eye-drug market and raises doubts about EyePoint's financing and development prospects.
9:57 AMBloomberg Markets
AstraZeneca Reports Mixed Lung Cancer Trial Results
Summary
AstraZeneca is stopping a late-stage trial of volrustomig after the experimental drug appeared unlikely to outperform existing lung cancer treatments. Separate trials produced positive results, including a Tagrisso and Orpathys combination for non-small cell lung cancer.
The decision removes one potential lung cancer asset, but the successful trials strengthen AstraZeneca's existing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AstraZeneca's lung cancer strategy remains viable, but its next growth phase will depend more heavily on proven franchises and combination therapies.
9:22 AMStat News
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
Summary
AstraZeneca is discontinuing a late-stage trial testing a drug in patients with metastatic non-small cell lung cancer. The decision adds to a recent run of setbacks for the company’s oncology pipeline.
The halted trial removes another late-stage opportunity in a highly competitive lung cancer market and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A late-stage failure can weaken a drugmaker’s growth outlook and reduce future treatment options for patients with advanced lung cancer.
12:01 AMStat News
STAT+: State laws may be curbing private equity takeovers of physician group
Summary
Private equity deals involving practice-management firms are declining sharply, as new state laws appear to be limiting investor takeovers of physician groups.
The shift suggests lawmakers are beginning to constrain private equity's role in medical practice ownership.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
State ownership rules are starting to alter who can control physician practices and how healthcare consolidation proceeds.
12:00 PMMarketWatch
‘It’s a double-edged sword’: My husband got a $42,000 bonus. Will it wipe out our Affordable Care Act subsidy?
Summary
A household is weighing whether a $42,000 bonus could raise its income enough to reduce or eliminate its Affordable Care Act subsidy. The financial pressure has led to advice to return the bonus and borrow against home equity.
The bonus may create a tax and insurance-cost problem because ACA subsidy eligibility depends on
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
ACA subsidies can turn irregular income into a major insurance liability, making tax planning part of healthcare planning.
3:00 PMMarketWatch
My son does not work, yet pays $500 for Affordable Care Act health insurance. Is that fair?
Summary
The article examines a family's concern that an unemployed son pays $500 a month for Affordable Care Act coverage while some people with substantial assets but low taxable income qualify for subsidies. The dispute centers on how Marketplace assistance is calculated.
ACA subsidies are generally tied to reported household income, not wealth or employment status, which
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The subsidy rules shape who can afford coverage and remain a persistent flashpoint in debates over ACA reform.
Other Developments
A curated list of other prominent stories from this day.
Lupin received USFDA approval for generic pitolisant tablets, a treatment for excessive daytime sleepiness, strengthening its US generics portfolio. The stock remains below most key moving averages despite the approval, while foreign institutional investors increased their stake and mutual fund holdings fell.
11:25 PMEconomic Times
Sanofi plans to lay off 229 employees in Massachusetts, roughly a year after completing its $9.1 billion acquisition of Blueprint Medicines. The cuts affect one of the state's largest pharmaceutical employers.
3:23 PMStat News
Eli Lilly and Johnson & Johnson shares rose after investors assessed new company data, while software stocks surrendered some of their gains from the previous week. The session reflected a rotation between healthcare names and higher-valued technology stocks.
2:42 PMCNBCPaleoanthropologist Daniel Lieberman discusses how evolutionary adaptations shape appetite, body fat and responses to modern diets, as well as the conflicting evidence behind nutrition advice.
1:23 PMNPR Arts
Healthcare providers are increasingly treating financing as part of the checkout process for costly services, including dental, vision and veterinary care. Payment timing can determine whether patients proceed with, reduce or delay treatment.
12:24 PMPYMNTS
The lung cancer drug developed by Akeso and Summit is showing a worsening benefit on tumor progression. The broader biotech update also covers Europe's withdrawal of Tavneos over trial-integrity concerns and pricing questions around AstraZeneca's hypertension drug.
9:38 AMStat News
In a 16-week clinical trial, participants following a low-fat vegan diet consumed about 357 fewer calories per day without counting calories, reducing portions or reporting persistent hunger. They ate nearly the same amount of food overall, with the change linked to the foods' lower calorie density.
9:07 AMScienceDaily
Researchers found that triple-negative breast tumors may recruit macrophages to release BDNF, a protein that draws nerves into the tumor. These nerves may then support tumor growth, treatment resistance and spread.
8:06 AMScienceDaily
The administration issued an executive order reshaping the federal vaccine agenda, while Epic faced antitrust lawsuits and other health policy developments unfolded during the week. The review also covers the administration's broader health care actions.
8:03 AMStat News
Pediatrician Nishant Pandya argues that paid paternity leave should be treated as a form of preventive care. He points to evidence that fathers make distinct contributions to children's health and development.
4:30 AMStat News
Epic is preparing for its annual User Group Meeting while facing an unusually difficult set of demands from the hospitals that rely on its software. The company is expected to use the meeting to address customers and present its future road map.
4:30 AMStat News
Mandy Cohen and Kody Kinsley argue that North Carolina's health reforms show pragmatic, bipartisan policymaking can produce results. They call for applying that approach nationally.
4:30 AMStat NewsRobert F. Kennedy Jr.’s California trip focused on fraud and addiction while vaccine issues dominated discussions in Washington. The contrasting agendas reflected his emphasis on selected Make America Healthy Again themes and his avoidance of more divisive subjects.
4:30 AMStat NewsArgenx shares rose after the company reported another large successful trial for Vyvgart, its leading autoimmune drug.
4:03 AMBloomberg Markets
A developmental screening tool is used in New York State less often than in almost any other state. Officials are launching a campaign to increase its use and identify developmental concerns earlier.
1:07 PMNYT New York11:25 PMEconomic Times
Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness
Summary
Lupin received USFDA approval for generic pitolisant tablets, a treatment for excessive daytime sleepiness, strengthening its US generics portfolio. The stock remains below most key moving averages despite the approval, while foreign institutional investors increased their stake and mutual fund holdings fell.
The approval adds a new commercial opportunity but does not yet change the stock's weak
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The approval could support Lupin's US growth, but execution and market competition will determine whether it translates into earnings and a sustained share-price recovery.
3:23 PMStat News
STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
Summary
Sanofi plans to lay off 229 employees in Massachusetts, roughly a year after completing its $9.1 billion acquisition of Blueprint Medicines. The cuts affect one of the state's largest pharmaceutical employers.
The layoffs show Sanofi is reducing its local workforce even after using the acquisition to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The cuts raise questions about whether large pharmaceutical acquisitions create durable local growth or mainly consolidate operations.
2:42 PMCNBC
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
Summary
Eli Lilly and Johnson & Johnson shares rose after investors assessed new company data, while software stocks surrendered some of their gains from the previous week. The session reflected a rotation between healthcare names and higher-valued technology stocks.
The immediate shift was toward healthcare stocks with fresh data catalysts and away from software
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The moves show how clinical and product data can redirect capital quickly across competing parts of the market.
1:23 PMNPR Arts
'Fed Up' author explains how evolution impacts eating, dieting and fat
Summary
Paleoanthropologist Daniel Lieberman discusses how evolutionary adaptations shape appetite, body fat and responses to modern diets, as well as the conflicting evidence behind nutrition advice.
The central point is that weight loss often collides with biological systems shaped to defend
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
An evolutionary lens challenges weight-loss narratives that place most responsibility on individuals.
12:24 PMPYMNTS
Patient Financing Becomes Part of the Healthcare Checkout
Summary
Healthcare providers are increasingly treating financing as part of the checkout process for costly services, including dental, vision and veterinary care. Payment timing can determine whether patients proceed with, reduce or delay treatment.
The shift moves financing from a back-office collection tool into the point-of-care purchasing decision. Providers
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Embedding credit in healthcare checkout can expand access and revenue while making medical debt a more immediate consumer-finance risk.
9:38 AMStat News
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
Summary
The lung cancer drug developed by Akeso and Summit is showing a worsening benefit on tumor progression. The broader biotech update also covers Europe's withdrawal of Tavneos over trial-integrity concerns and pricing questions around AstraZeneca's hypertension drug.
The deteriorating tumor-progression result weakens the drug's clinical and commercial outlook and could force investors
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A weakening efficacy signal can undermine a major oncology program even as other regulatory and pricing pressures raise the sector's risk profile.
9:07 AMScienceDaily
Low-fat vegan diet helps people lose weight without eating less
Summary
In a 16-week clinical trial, participants following a low-fat vegan diet consumed about 357 fewer calories per day without counting calories, reducing portions or reporting persistent hunger. They ate nearly the same amount of food overall, with the change linked to the foods' lower calorie density.
The diet changed calorie intake through food composition rather than stricter restraint. That could make
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The findings support dietary approaches that reduce energy intake without relying on hunger, tracking or portion control.
8:06 AMScienceDaily
Scientists uncover the hidden nerve network fueling breast cancer
Summary
Researchers found that triple-negative breast tumors may recruit macrophages to release BDNF, a protein that draws nerves into the tumor. These nerves may then support tumor growth, treatment resistance and spread.
The discovery identifies a potential cancer-supporting circuit linking immune cells, nerves and tumor tissue. If
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A previously overlooked interaction between the immune and nervous systems may help explain why aggressive breast cancers resist treatment.
8:03 AMStat News
Everything the Trump administration did on health care last week
Summary
The administration issued an executive order reshaping the federal vaccine agenda, while Epic faced antitrust lawsuits and other health policy developments unfolded during the week. The review also covers the administration's broader health care actions.
The vaccine order signals a federal shift in how health policy priorities and oversight may
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Federal vaccine policy and health-tech consolidation could change how patients, providers and drug companies operate.
4:30 AMStat News
Opinion: Paid paternity leave is pediatric preventive care
Summary
Pediatrician Nishant Pandya argues that paid paternity leave should be treated as a form of preventive care. He points to evidence that fathers make distinct contributions to children's health and development.
The case reframes paid leave as an intervention that can improve child health, not simply
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Treating paid paternity leave as preventive care could broaden support for family policy within health systems and public programs.
4:30 AMStat News
STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road map
Summary
Epic is preparing for its annual User Group Meeting while facing an unusually difficult set of demands from the hospitals that rely on its software. The company is expected to use the meeting to address customers and present its future road map.
Epic's dominant position makes its next priorities consequential for hospitals, clinicians, and patients across the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Epic's product decisions can set the pace for health-record interoperability, clinical workflows, and technology spending across much of American medicine.
4:30 AMStat News
Opinion: We proved bipartisan health care reform works in North Carolina. Let’s bring it nationwide
Summary
Mandy Cohen and Kody Kinsley argue that North Carolina's health reforms show pragmatic, bipartisan policymaking can produce results. They call for applying that approach nationally.
The argument rests on treating North Carolina as evidence that cross-party cooperation can overcome health
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The debate shifts from whether bipartisan reform is possible to whether its conditions can survive at national scale.
4:30 AMStat News
STAT+: Kennedy’s split-screen week: Talk of vaccines in D.C., fraud and addiction out West
Summary
Robert F. Kennedy Jr.’s California trip focused on fraud and addiction while vaccine issues dominated discussions in Washington. The contrasting agendas reflected his emphasis on selected Make America Healthy Again themes and his avoidance of more divisive subjects.
Kennedy is separating his public-health agenda by audience and venue rather than advancing one unified
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Kennedy’s issue-by-issue strategy could expand his coalition while obscuring how his department would handle its most contentious responsibilities.
4:03 AMBloomberg Markets
Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart
Summary
Argenx shares rose after the company reported another large successful trial for Vyvgart, its leading autoimmune drug.
The result adds to Vyvgart's clinical validation and strengthens the case for expanding its use
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
More positive data could extend Vyvgart's market opportunity and increase pressure on competing autoimmune treatments.
1:07 PMNYT New York
There’s a Way to Gauge Childhood Development. Why Isn’t It Used More?
Summary
A developmental screening tool is used in New York State less often than in almost any other state. Officials are launching a campaign to increase its use and identify developmental concerns earlier.
New York’s low screening rate creates a gap between children who may need support and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
More consistent screening could connect children to developmental services before problems become harder and more expensive to address.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!